Biomedical Engineering Reference
In-Depth Information
110. Grenadier E, Keidar S, Alpan G et al (1980) Prenylamine-induced ventricular tachycardia
and syncope controlled by ventricular pacing. Br Heart J 44:330-334
111. Sanguinetti MC, Chen J, Fernandez D et al (2005) Physicochemical basis for binding and
voltage-dependent block of hERG channels by structurally diverse drugs. Novartis Found
Symp 266:159-166; discussion 166-170
112. Ando K, Sugiyama A, Takahara A et al (2007) Analysis of proarrhythmic potential of
antipsychotics risperidone and olanzapine in anesthetized dogs. Eur J Pharmacol 558:
151-158
113. Haverkamp W, Breithardt G, Camm AJ et al (2000) The potential for QT prolongation and
pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report
on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 47:219-233
114. Gluais P, Bastide M, Grandmougin D et al (2004) Risperidone reduces K+ currents in human
atrial myocytes and prolongs repolarization in human myocardium. Eur J Pharmacol 497:
215-222
115. Gluais P, Bastide M, Caron J et al (2002) Risperidone prolongs cardiac action potential
through reduction of K+ currents in rabbit myocytes. Eur J Pharmacol 444:123-132
116. Botchway AN, Turner MA, Sheridan DJ et al (2003) Electrophysiological effects
accompanying regression of left ventricular hypertrophy. Cardiovasc Res 60:510-517
117. Magyar J, Banyasz T, Bagi Z et al (2002) Electrophysiological effects of risperidone in
mammalian cardiac cells. Naunyn Schmiedebergs Arch Pharmacol 366:350-356
118. Brown K, Levy H, Brenner C et al (1993) Overdose of risperidone. Ann Emerg Med
22:1908-1910
119. Sanguinetti MC, Jiang C, Curran ME et al (1995) A mechanistic link between an inherited and
an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 81:299-307
120. Wang J, Best PM (1994) Characterization of the potassium channel from frog skeletal
muscle sarcoplasmic reticulum membrane. J Physiol 477(Pt 2):279-290
121. Yap YG, Camm J (2000) Risk of torsades de pointes with non-cardiac drugs. Doctors need to
be aware that many drugs can cause qt prolongation. BMJ 320:1158-1159
122. Zimbroff DL, Kane JM, Tamminga CA et al (1997) Controlled, dose-response study of
sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am J
Psychiatry 154:782-791
123. Simons FE, Simons KJ (1994) The pharmacology and use of H1-receptor-antagonist drugs.
N Engl J Med 330:1663-1670
124. Tashibu H, Miyazaki H, Aoki K et al (2005) QT PRODACT: in vivo QT assay in
anesthetized dog for detecting the potential for QT interval prolongation by human
pharmaceuticals. J Pharmacol Sci 99:473-486
125. Martin RL, Su Z, Limberis JT et al (2006) In vitro preclinical cardiac assessment of
tolterodine and terodiline: multiple factors predict the clinical experience. J Cardiovasc
Pharmacol 48:199-206
126. Davis AS (1998) The pre-clinical assessment of QT interval prolongation: a comparison of
in vitro and in vivo methods. Hum Exp Toxicol 17:677-680
127. Dumotier BM, Georgieva AV (2007) Preclinical cardio-safety assessment of torsadogenic
risk and alternative methods to animal experimentation: the inseparable twins. Cell Biol
Toxicol 23:293-302
128. Towart R, Linders JT, Hermans AN et al (2009) Blockade of the I(Ks) potassium channel: an
overlooked cardiovascular liability in drug safety screening? J Pharmacol Toxicol Methods
60:1-10
129. Pugsley MK (2005) Methodology used in safety pharmacology: appraisal of the state-of-the-
art, the regulatory issues and new directions. J Pharmacol Toxicol Methods 52:1-5
130. Anonymous (2000) The European Agency for the Evaluation of Medicinal Product. Human
Medicine Evaluation Unit. ICH Topic S7. Safety Pharmacology Studies for Human Pharma-
ceuticals. Note for Guidance on Safety Pharmacology Studies in Human Pharmaceuticals.
(CPMP/ICH/539/00)
